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The incidence of bladder cancer varies throughout the world
(Boring et al, 1994). The highest incidence rates are generally
found in industrially developed countries, particularly North
America and Western Europe, and in areas associated with
endemic Schistosomiasis infection, including parts of Africa and
the Middle East (Parkin et al, 1993). The vast majority (90%) of
tumours of the urinary bladder is of urothelial origin, arising from
the specialized transitional type of epithelium that lines the
bladder. Because of the multipotential nature of the urothelium,
tumours of other types; squamous, glandular, and neuroendocrine;
can also arise (Brodsky, 1992). 
It is generally accepted that, as with most other carcinomas,
bladder cancer development is dependent on a combination of
genetic and environmental factors. Although no genetic progres-
sion model has been defined for bladder cancer, multiple genetic
alterations have been identified in primary bladder tumours even
at their very early stages (Mao, 1996). Genetic alteration in one or
more of three categories of genes has been almost universally
connected to cancer development. These include proto-oncogenes,
tumour suppressor genes, and genes that function in damage
recognition and repair (Lairmore and Norton, 1997). 
The existence of mismatch repair (MMR) enzymes in bacteria
has been known for at least two decades and more recently similar
activities have been identified in yeast and higher eukaryotes
(Modrich, 1991). Mutations of MMR genes have been shown to be
associated with colorectal and other cancers in the hereditary
nonpolyposis colorectal syndrome (HNPCC), as well as a propor-
tion of sporadic colorectal cancers (Lairmore and Norton, 1997).
Mutational inactivation of both copies of DNA MMR genes results
in a profound repair defect which is presumed to lead to progressive
accumulation of secondary mutations throughout the genome,
some of which affect important growth regulatory genes and hence
give rise to cancer (Peltomaki and de la Chapelle, 1997). 
The protein products of MMR genes (MSH2, MLH1, PMS1,
PMS2, GTBP or MSH6) act in concert as part of complexes to
enable the recognition and excision of mis- or unmatched bases.
MSH2 and MLH1 proteins are vital, which may explain why the
majority of HNPCC mutations occur in either MSH2 or MLH1
(Frayling, 1999). MMR plays an important role in maintaining
replication fidelity, processing and regulating recombination
(Kolodner, 1995). Mutation in any of the genes required to main-
tain the integrity of the genome will result in a state of genetic
instability, a ‘mutator’ phenotype, which could contribute to the
accumulation of mutations required for multistage carcinogenesis
(Loeb, 1991, 1994). 
Microsatellites are stably inherited short tandem repeat DNA
sequences that are unique to each individual (Brentnall, 1995).
Microsatellite instability (MSI) appears as aberrant-sized alleles
resulting from a gain or loss of short repeat units in tumour DNA
in comparison to normal DNA. MSI serves as a useful marker of a
mutator phenotype (Peltomaki, 1997) which is a characteristic of
HNPCC (Aaltonen et al, 1993, 1994) and reflects malfunctions in
the replication or repair of DNA (Aaltonen et al, 1993).
Biochemical studies have provided a link between MSI and defect-
ive MMR (Parsons et al, 1993). In addition to HNPCC, MSI has
been observed in several sporadic tumours (Han et al, 1993;
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studies have reported the occurrence of MSI in bladder cancer
(Gonzalez-Zulueta et al, 1993; Mao et al, 1994, 1996; Orlow et
al, 1994; Uchida et al, 1996; Steiner et al, 1997; Christensen et al,
1998; Mourah et al, 1998). Recently, the tumour spectrum associ-
ated with germline mutations of MMR genes in HNPCC cases was
found by Aarnio et al (1999) to involve several organs including
the uro-epithelium. These studies may point to the possibility of
involvement of mismatch repair genes in sporadic bladder cancer,
thus the authors were interested in assessing MMR status in
bladder cancer in the context of quantitative expression and detec-
tion of microsatellite instability at the regions of the MMR genes:
MSH2 and MLH1. 
MATERIALS AND METHODS 
Samples 
Fifty seven bladder tumour samples (44 TCC and 13 SCC) were
obtained from radical cystectomy specimens from the Department
of Urology, Faculty of Medicine, Alexandria University. The
patients’ mean age was 56.7 ± 8.6 years (ranging from: 38–71
years). Forty three patients were male (75%) and 14 were female
(25%). Sixty eight percent of patients (39/57) self-reported a history
of either a positive test (presence of bilharzial eggs in urine) or
past treatment for schistosomiasis. Tissues collected included
grossly obvious tumour tissue that was confirmed by subsequent
histopathological diagnosis at the Pathology Department, Faculty
of Medicine, Alexandria University. Samples were immediately
frozen on dry ice, stored at –70˚C and were transferred on dry ice
to the Paterson Institute for Cancer Research in Manchester where
they were analysed. DNA was extracted from paired frozen
bladder samples (grossly obvious tumour and macroscopically
non-involved mucosa obtained as far from the site of tumour as
possible) using proteinase K digestion and standard phenol chloro-
form extraction method (Sambrook et al, 1989). After taking the
tissue for DNA extraction, those samples that were large enough
were fixed in 4% buffered formaldehyde and processed to paraffin
wax. Representative haematoxylin and eosin stained sections were
examined microscopically to confirm the presence of tumour, and
to assess the percentage of tumour cells. All cases selected showed
at least 40% neoplastic cells amongst fibrous and muscular tissues. 
Immunohistochemical analysis of MLH1 and MSH2
proteins 
36 analysable samples (24 TCC and 12 SCC) were selected from
the formalin-fixed, paraffin embedded sections and serial 3 mm
thick sections were cut and subbed on APES (3-aminopropyltri-
ethoxysilane from Sigma) coated slides. Sections were deparaf-
finized through xylene and graded alcohol. The sections were then
treated by microwaving to retrieve antigens in 1 litre of 10 mM
citrate buffer (pH 6.0) for 30 min at 700 W, and allowed to cool.
Endogenous peroxidase activity was blocked by incubating in 1%
H2O2/100% methanol for 30 min. Non-specific protein binding
was eliminated by incubation for 30 min at room temperature 
in 5% normal rabbit serum (Dako). Sections were incubated
overnight at 4˚C with the primary antibody at a dilution of
5  mg ml–1 and 10 mg ml–1 of mouse monoclonal antihuman MLH1
and MSH2 immunoglobulins, respectively (PharMingen).
Sections were then incubated with biotinylated rabbit anti-mouse
antibody (Dako). Binding sites were visualized using standard
avidin–biotin complex method (Hsu et al, 1981). Sections were
counterstained with propidium iodide 2.5 mg ml–1 (Sigma).
Positive controls consisting of sections of human colon and negat-
ive controls, in which TBS was used instead of primary antibody,
were included with every batch. Initially, samples were subject-
ively screened and this was followed by analysis of 5–10 fields
(depending on the section size) using Lucia G image analysis soft-
ware package which automates data collection. The negative
control section for each sample was used to set a threshold above
which staining in the immune-stained sections was defined by the
analysis system as positive. Thus any background staining was
excluded. The total number of tumour cells was determined in the
analysed fields by applying a series of semi-automated steps
which counts positive-staining cells then adds this number to the
negative-staining tumour cells which are counted by virtue of their
propidium iodide fluorescence due to lack of the quenching effect
of the DAB in the unstained cells. The image analysis thus
provides a measure of the total and the positive-stained cells from
which the percentage positivity is calculated. 
Microsatellite analysis at hMSH2 and hMLH1 loci 
A PCR-based method was used to assess allellic loss and/or alter-
ations occurring at loci which lie within, or in close proximity to,
MSH2 (2p16) and MLH1 (3p21) genes. Three dinucleotide
microsatellite repeats on chromosome 2p16 (D2S123, D2S391,
D2S119) and 3p21 (D3S1612, D3S1611, D3S1561) were used.
Primer sequences were taken from the 1993–94 Genethon human
genetic linkage map (Gyapay et al, 1994). 
PCR amplification was carried out in a 10 ml reaction mix using
standard microsatellite analysis PCR method (Varley et al, 1999).
Annealing temperature for D3S1611 marker was adjusted at 62˚C
rather than 56˚C to eliminate non-specific bands. Products were
separated on 6% denaturing polyacrylamide sequencing gels
(National Diagnostics) and dried before exposure overnight to Fuji
RX film at -70˚C. Autoradiographs were scored by 2 independent
examiners. Loss of heterozygosity (LOH) was scored when there
was complete loss of one allele in an informative sample (i.e. the
normal DNA was heterozygous), and allellic imbalance (AI) was
scored when there was an observed difference in intensity of the
alleles between tumoral and normal DNA. Change in allele size or
the appearance of a new band in tumoral DNA was scored as new
allele (NA). Only informative samples at any of the loci analysed
for each gene were included in the calculation of the frequency of
allelic loss. 
RESULTS 
Immunohistochemical analysis of MSH2 and MLH1
proteins 
Immunohistochemical staining of MSH2 and MLH1 showed
exclusively nuclear staining in both normal and tumour cells. IHC
staining of samples of normal urothelium from non-invovled
mucosa obtained from radical cystectomy specimens showed relat-
ive homogeneity of expression of MMR proteins (Figure 1) with
basal, middle and superficial cells all showing positive staining.
Metaplastic squamous epithelium of the bladder showed staining
of basal cells, most of the middle cell layer (prickle zone) but with
faint or even absent staining of the most superficial flattened cell
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urothelium. 
Initial subjective screening of tumour sections revealed inter-
and intratumoral heterogeneity (Figure 2). The staining pattern
varied considerably amongst different tumour samples. Some
tumours stained relatively homogeneously as shown in Figure 2 (A
and B). Heterogeneity within the tumours was frequently observed
for both MSH2 and MLH1 in which clusters of cells showed low
or relatively absent staining amongst positive-stained cells as
shown in Figure 2 (C and D), or occasional positive cells might be
found randomly in a generally low expressing tumour as shown in
Figure 2 (E and F). Although complete loss of expression of
MSH2 and MLH1 was infrequently encountered (one SCC (1/12,
8%) and one TCC (1/24, 4%) lost MSH2 and one TCC lost MLH1
(1/24, 4%), a large proportion of tumours revealed less than 50%
positive-stained nuclei for both MSH2 and MLH1 (69% and 44%
respectively). 
The number of positively stained cells was determined using a
threshold defined by the use of tris-buffered saline in place of the
immune serum. A wide range of expression of MMR proteins was
observed in both pathologic types of bladder cancer (Figure 3).
There was no correlation between expression of MSH2 and MLH1
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Figure 1 Immunohistochemical staining of normal urothelium (top row) and
metaplastic squamous epithelium (bottom row) for MSH2 and MLH1, (320
magnification). The superficial (S), middle (M), and basal (B) cell layers are
indicated by arrows  Colour version available online at http://www.idealibrary.
com and http://www.paterson.man.ac.uk/carcinogenesis
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Figure 2 Representative MSH2 and MLH1 immunostained tumour sections
(A, B, D, E are TCCs and C and F are SCCs), (x20 magnification). Note the
heterogeneity in the level of expression between different tumour sections.
Regional (C and D) and intercellular (E and F) heterogeneity observed within
the same tumour marked by arrows in (C, D, E, and F) and explained in
detail in the text. Colour version available online at http://www.idealibrary.
com and http://www.paterson.man.ac.uk/carcinogenesis
120
100
80
60
40
20
 0
TCC SCC
A(MSH2)
120
100
80
60
40
20
 0
120
100
80
60
40
20
 0
TCC SCC
B(MLH1)
C
0 20 40 60 80 100 120
R2 = 0.0452
%
 
o
f
 
p
o
s
i
t
i
v
e
 
M
S
H
2
 
s
t
a
i
n
e
d
 
c
e
l
l
s
%
 
o
f
 
p
o
s
i
t
i
v
e
-
s
t
a
i
n
e
d
 
c
e
l
l
s
% of positive MLH1 stained cells
Figure 3 Intertumoural heterogeneity and wide range of expression of
MSH2 (A) and MLH1 (B) expression in TCC and SCC, and the relationship
between both mismatch repair proteins in all samples analysed (C) (Figure 3). Table 1 summarizes the findings in the two pathologic
types. The coefficient of variation for both proteins was high,
confirming the observer-reported intertumoral heterogeneity
within TCC and SCC samples. The mean percentage positivity of
MSH2 in SCC was observed to be half that of MLH1 in the same
pathologic subtype; this proved to be statistically significant
(P = 0.02 using Wilcoxon Signed Ranks test) (Table 1). It was also
observed that the mean percentage positivity of MSH2 in SCC was
lower than that in TCC, however this was not found to be
statistically significant (P = 0.2 using the Mann-Whitney 2-tailed
test) (Table 1). The relationship between the bilharzial status and
the levels of expression of MLH1 and MSH2 was studied using
the Mann-Whitney test and revealed a statistically significant
difference in the level of expression of MLH1 but not MSH2 in the
schistosomal positive versus negative samples (P = 0.01, 0.9
respectively). The samples were further stratified into TCC and
SCC in relation to the bilharzial status and a significant difference
was still observed in SCC but not in the TCC group (P = 0.04,
0.15, respectively). 
Results of microsatellite analysis 
Allelic loss was assessed at the markers flanking hMSH2 on chromo-
some 2p16 and hMLH1 on 3p21 using microsatellite repeats as
close together as possible to detect small regions of deletion
(Gyapay et al, 1994; Tomlinson et al, 1996). Representative
autoradiographs of the gels used for scoring in this study are
shown in Figure 4. Tables 2A and 2B list the allellotypes of
samples showing any alterations at the microsatellite loci studied
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Table 2 The allelotypes of those samples showing alterations at (A) 2p16 and (B) 3p21, and the expression of the
corresponding MMR protein 
A
Sample code Microsatellite loci at 2p16 IHC of MSH2
(% positivity) 
D2S123 D2S391 D2S119 
3 cM 5 cM 
H1 NI AI AI 8 
H7 NI AI NI ND 
H13 NI AI AI 27 
H30 ROH AI AI 13 
A4 AI ROH ROH 100 
A9 NI AI AI 54 
A11 ROH NI AI 37 
A21 LOH NA NA ND 
A29 ROH AI NI 34 
A32 AI AI NI ND 
A35 AI ROH NI 46 
B 
Sample code Microsatellite loci at 3p21 IHC of MLH1
(% positivity) 
D3S1612 D3S1611 D3S1561 
0 cM 0 cM 
H1 NI NI AI 85 
H7 AI ROH NI ND 
H22 NI ROH AI 42 
H27 AI AI NI 4 
H30 ROH AI NI 55 
A4 LOH LOH LOH 89 
A10 NI NI AI 87 
A11 AI AI NI 70 
A21 LOH NA NA ND 
A29 ROH AI NI 21 
A33 AI AI NI ND 
A34 AI AI NI 100 
A35 AI AI ROH 31 
A9 ROH ROH NA 3 
ROH: retention of heterozygosity, NI: non-informative for heterozygosity, AI: allelic imbalance, LOH: loss of heterozygosity, NA:
new allele or shift of size of an existing allele, ND: not done. 
Table 1 Percentage positivity of MMR proteins expression in TCC and SCC
samples 
MMR protein Percentage positivity TCC (24) SCC (12) Total (36) 
MSH2 Range 0–100% 0–46% 0–100% 
Mean 44.88 21.58 37.11 
Median 28.00 20.50 23.50 
SD 38.78 15 34.40 
Coefficient of variation 86% 70% 93% 
MLH1 Range 0–100% 10–79% 0–100% 
Mean 53.46 45.17 50.69 
Median 59.00 47.50 52.50 
SD 35.79 19.63 31.28 
Coefficient of variation 67% 43% 62% along with their corresponding immunohistochemical status
expressed as percentage positivity. 
Complete LOH was infrequently encountered. Only one TCC
sample (A21; 1/42 i.e. 2%) of the informative samples revealed
LOH at one of the markers on chromosome 2p (D2S123). Two
TCC samples revealed LOH at chromosome 3p markers (2/44
(5%)), one sample (A4) revealed LOH at the 3 loci analysed while
the other sample (A21), revealed LOH at D3S1612 only. Complete
LOH was not detected in any of the SCC samples analysed. The
incidence of AI was, however, higher than LOH. This could be due
to heterogeneity within the tumour and allelic loss occurring in a
subpopulation of tumour cells and therefore would be in agree-
ment with the observed intratumoral heterogeneity in expression
of MMR proteins. An alternative explanation is that DNA was
extracted from visible tumour tissue allowing contamination by
normal cells. The frequency of allelic loss (AI and LOH) at the
markers flanking MSH2 and MLH1 genes was higher in SCC (38%
for both genes) than in TCC (14% and 18%, respectively), but the
difference was not statistically significant using Fisher’s Exact test
(P = 0.3 and 0.5, respectively). There was no effect of the
bilharzial status on the incidence of microsatellite alterations at the
studied loci (Fisher’s Exact test, P = 1). 
Allelic imbalance and LOH occurred at markers compatible
with the involvement of hMSH2 and  hMLH1 genes. AI was
detected in the furthest marker studied on chromosome 3p21 in
sample H22, however, the IHC finding supported the possibility of
involvement of MLH1 in a sub-population of these tumours as the
percentage positivity was 42%. Samples that were found to be
negative for expression of MSH2 (H12, H22) and MLH1 (H13)
did not reveal AI at the flanking microsatellite loci, this could
be due to the fact that those samples were non-informative at the
studied loci or due to another mechanism of mutation of the in-
volved MMR gene. Sample A4 showed LOH at loci flanking
MLH1, and whilst IHC showed a high percentage positivity (89%)
for this protein, the intensity of staining was very faint. This may
suggest a structural alteration in the expressed protein with
reduced affinity for the antibody rather than a technical problem as
this sample stained very strongly for MSH2. There was no
observed difference in the means of the percentage positivity of
expression of MMR proteins in relation to the occurrence of alter-
ations at the loci flanking each or both of the genes (Table 3). Thus,
the two methods of analysis independently detected possible alter-
ations in structure and/or expression of MSH2 and MLH1 genes. 
The appearance of a new allele or shift of an existing allele
(NA) was detected in two samples. One of them (A21) revealed
NA at both 2p16 and 3p21 indicating the presence of a potential
mutator phenotype in this tumour which also showed LOH at one
of the loci flanking both hMSH2 and  hMLH1. To exclude the
possibility of PCR contamination or crossing of samples, DNA
was again extracted from the original tissues of this sample
(tumour and mucosa) and the results were confirmed.
Unfortunately, tumour tissue was not available to study the expres-
sion of MMR proteins in this sample. The samples analysed in this
study were all advanced bladder cancer (at least stage T2 and
grades 2 and 3), so it was not possible to assess MMR status in the
early stages of bladder cancer from the cohort studied. 
DISCUSSION 
Earlier studies have suggested that MMR deficiency results in an
increased rate of spontaneous mutation, giving the hallmark of a
mutator phenotype (Cox, 1973, 1976). MSI serves as a useful
marker of the mutator phenotype that is characteristic of HNPCC
(Aaltonen et al, 1993, 1994) and has been attributed to mutations
in one of several MMR genes including hMSH2, hMLH1, hPMS1
and hPMS2 (Leach et al, 1993; Bronner et al, 1994; Fishel et al,
1994; Nicolaides et al, 1994; Papadopoulos et al, 1994). MSI has
been described in a variety of sporadic cancers, such as colon
(Thibodeau et al, 1993), endometrium (Risinger et al, 1993)
pancreas and stomach (Han et al, 1993) and prostate (Uchida et al,
1996). Previous studies have also reported a high frequency of
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Figure 4 Representative autoradiographs of the scoring used in this study.
ROH: retention of heterozygosity, NI: non-informative of heterozygosity, LOH:
loss of heterozygosity, AI: allelic imbalance, NA: new allele (appearance of a
new allele or change of size of an existing allele). NB: in each case normal
DNA (extracted from non involved mucosa) is in the left lane and tumour
DNA is in the right lane 
Table 3 Summary of the correlation of IHC (percentage positivity) and
microsatellite alteration at 2p16 and 3p21 
Allelotype of Ioci on 2p16 and 3p21 Mean percentage positivitya
MSH2 MLH1 
No change (n = 21) 38.5 52.5 
Changes present on either 2p  36.7 48.9 
or 3p markers (n = 12)
Changes at 2p (n = 8) 40 44 
Changes at 3p (n = 11) 37.6 53.4 
aThe means of the percentage positivity for each group. MSI in bladder cancer (Mao et al, 1996; Steiner et al, 1997;
Mourah et al, 1998). The finding of MSI in a varying proportion of
sporadic cancers suggests that the same type of genetic defects in
MMR genes that underlie HNPCC can occur somatically in some
sporadic cancers including bladder cancer. However, the propo-
rtion of sporadic tumours in which MMR genes have been inactiv-
ated has not yet been clearly established (Kane et al, 1997). This
might be due to the fact that the methods available for detecting
mutations in these genes are laborious, and no single method is
capable of detecting all the types of mutations that could exist.
This is particularly problematic when tumour samples are
analysed because of the contamination of tumour cells with
normal tissue in such samples and also due to the fact that the
complete spectrum of mutations and modes of inactivation applic-
able to the analysis of these genes is not currently known (Kane et
al, 1997). In a clinical setting, the use of IHC appears to offer a
relatively convenient and rapid method for prescreening tumours
for defects in the expression of mismatch repair genes (Thibodeau
et al, 1996). 
In the present study alterations in hMSH2 and hMLH1 were
determined in TCC and SCC of the bladder using quantitative
immunohistochemistry and PCR-based microsatellite analysis
methods. IHC analysis showed nuclear localization of staining as
reported in previous studies (Lim et al, 1996; Thibodeau et al,
1996; Fink et al, 1997). Immunostaining of normal urothelium
revealed a relatively homogeneous staining of almost all cells as
shown in Figure 1. This is the first report of the pattern of staining
of the normal urothelium for these MMR proteins. Intratumoral
heterogeneity was observed in the majority of samples. Intra-
tumoral heterogeneity in MLH1 and MSH2 gene alterations has
previously been reported by Habano et al (1998) in sporadic
colorectal cancer using a sensitive technique for allelic loss detec-
tion in different crypts within the same tumour after microdissec-
tion. This is therefore in agreement with our findings using
immunohistochemistry, which has the benefits of being simpler
and more convenient. Metaplastic squamous epithelium showed
MSH2 and MLH1 staining of the basal cells and most of the
prickle cell layer which is comparable to that previously reported
for MSH2 staining of the squamous epithelial lining of the oesoph-
agus and MSH2 and MLH1 staining of the oral mucosa (Leach et
al, 1996 and Lo Muzio et al, 1999, respectively). 
The absence of MLH1 and MSH2 immunostaining was previ-
ously correlated with the presence of mutation in the cor-
responding gene in sporadic colon cancer (Thibodeau et al, 1996).
Such complete absence of expression of MSH2 and MLH1 was
infrequently encountered in the present study. However, a large
proportion of tumours revealed a percentage positivity of less than
50% for MSH2 and MLH1 (69% and 44%, respectively). The
statistically significant lower level of expression of MSH2 in
comparison to MLH1 in SCC suggests the possible greater
involvement of MSH2 than MLH1 in SCC tumorigenesis and/or
progression. The statistically significant difference in the expres-
sion of MLH1 in relation to the bilharzial status might suggest a
possible role of schistosomiasis in altering the expression of
MLH1 in SCC, however this should be further investigated. 
In HNPCC, defective MMR is a very early event (Parsons et al,
1995), while in sporadic non-small cell lung carcinoma it has been
suggested that defective MMR is a later event related to lung
tumour progression (Wieland et al, 1996). The present study
suggests that MMR deficiency in bladder cancer is likely to occur
during tumour progression rather than as an initiating event since
the majority of the samples analysed revealed intratumoral hetero-
geneity in expression of MMR proteins rather than complete loss
in all cells of the tumour. The present study involved only
advanced stages (at least T2) and advanced grades (2 and 3) of
bladder cancer. In this patient group it was therefore not possible
to correlate the MMR involvement with tumour progression. The
observed intertumoral variation in the expression of these proteins
might have prognostic implications regarding outcome or response
to therapy. Jin et al (1999) suggested that reduction in expression
of MSH2 in TCC of the bladder might be useful in predicting
recurrence. 
Tumour suppressor and MMR genes share the requirement for
homozygosity at the cellular level and somatic deletion is a
common event in both (Hemminki et al, 1994). This second muta-
tional step may be revealed as LOH, which was previously reported
at the hMLH1 locus in HNPCC (Hemminki et al, 1994) as well as at
hMLH1 and hMSH2 loci in sporadic colorectal cancers (Tomlinson
et al, 1996; Benachenhou et al, 1998b), in non-small cell lung
cancer (Benachenhou et al, 1998a) and in breast cancer
(Benachenhou et al, 1999). Christensen et al (1998) reported the
occurrence of LOH at microsatellites located close to hMSH2 and
hMLH1 and suggested a possible role of these genes in causing
profound MSI in bladder cancer. Allelic loss at 3p was previously
reported by Rosin et al (1995) and Li et al (1996) which may
suggest involvement of hMLH1 in TCC of the bladder. However
these studies analysed only TCC and did not include other methods
of analysis to confirm hMLH1 involvement. In the present study,
allelic loss was studied at loci (D2S123, D2S391 and D2S119)
which are known to be linked to hMSH2 (Leach et al, 1993).
D3S1611 is known to lie within an intron of hMLH1
(Papadopoulos et al, 1994). Benachenhou et al (1998a) found that
the shortest region of overlapping deletions for 3p21 was delimited
by D3S1561 and D3S1612. Allelic loss (LOH or AI) was detected
in TCC (14% on 2p16 and 18% on 3p21) and in SCC (38% on 2p16
and 38% on 3p21). However, the frequency of allelic loss in the
present study should be considered conservative since DNA was
not extracted by microdissection and hence some allelic losses
could have been masked by contaminating material from normal
cells. The frequency of allelic loss at MLH1 in TCC (18%) was
similar to that found in sporadic colorectal cancer (17%;
Benachenhou et al, 1998b and 16%; Tomlinson et al, 1996).
Whereas in SCC the frequency of allelic loss at MLH1 was 
higher (38%), which was comparable with that detected in breast
cancer (46%; Benachenhou et al, 1999) and non-small cell lung
cancer (43%; Wieland et al, 1996). The frequency of MSH2 allelic
loss in TCC detected in this study (14%) was comparable to that
detected in non-small cell cancer (11.5%; Benachenhou et al,
1998a) and also in sporadic colorectal cancer (15%; Benachenhou
et al, 1998b). A higher frequency of allelic loss at MSH2 was
detected in SCC of the bladder (38%). This together with the
finding of a low mean percentage positivity of expression of MSH2
in this pathologic type points to the possibility of a contributing role
of MSH2 gene in the pathogenesis of SCC of the bladder. 
Other alterations such as small deletions, point mutations, gene
rearrangements or DNA cytosine methylation, if they also cause
inactivation of both copies of these genes, would escape detection
by this PCR based allelic loss analysis method. Therefore, IHC
analysis was used to detect samples with deficiency in MMR that
was not detected by allelic loss analysis. H12 and H22 lacked
expression of MSH2 and H13 lacked MLH1 expression, even
though they had no evidence of LOH/AI of the corresponding gene.
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tional hot spots and lack of expression can occur without detectable
mutations (Liu et al, 1994). DNA methylation has been reported to
be a mode of hMLH1 gene inactivation in sporadic colon and
gastric carcinoma (Kane et al, 1997 and Leung et al, 1999, respect-
ively). A similar mechanism of inactivation by promotor methyla-
tion, or possibly by another mechanism of mutation might be
responsible for the lack of expression of MMR proteins in the
present samples. The samples scored as AI did display reduced
expression of the corresponding MMR gene in the majority of
cases, however there were exceptions. Sample A34 showed AI at
microsatellite loci flanking hMLH1, yet expressed high levels of
the protein, this however does not exclude the possibility of func-
tional disturbance of the expressed protein and another explanation
may be that the structural alteration may have not involved the anti-
body recognition sites. Also, although sample A4 revealed LOH at
all loci on chromosome 3p and whilst the percentage positivity for
expression of MLH1 was 89%, the intensity of staining was very
low, suggesting abnormal expression. As shown in Table 3 there
was no relationship between the expression (percentage positivity)
of the MMR proteins and the occurrence of microsatellite alter-
ations at the corresponding chromosome location. This suggests
that the two methods of analysis were useful in determining
changes that would not have been detected by either of them alone. 
In conclusion, this study reveals the occurrence of alterations in
the structure and expression of DNA mismatch repair genes and
suggests the possibility of involvement of these genes in tumorige-
nesis and/or progression of TCC and SCC of the bladder. IHC
offers a convenient and a rapid method for prescreening tumours
for defects in mismatch repair genes, but might not exclude the
structural and functional alterations of these proteins. Further
extensive studies would be required to establish whether or not in
bladder cancer and in other tumour types IHC may indeed be a
more reliable diagnostic test for MMR involvement. To the best of
our knowledge, this is the first study to demonstrate an involvement
of hMLH1 in TCC and SCC and of hMSH2 in SCC of the bladder. 
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